BiotechTube

Methylprednisolone

ApprovedCompleted
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Cluster Headache, Episodic

Conditions

Cluster Headache, Episodic, Greater Occipital Nerve Injection

Trial Timeline

Aug 1, 2019 → Aug 27, 2021

NCT ID
NCT04014634

About Methylprednisolone

Methylprednisolone is a approved stage product being developed by Brain Biotech for Cluster Headache, Episodic. The current trial status is completed. This product is registered under clinical trial identifier NCT04014634. Target conditions include Cluster Headache, Episodic, Greater Occipital Nerve Injection.

Hype Score Breakdown

Clinical
30
Activity
20
Company
2
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04014634ApprovedCompleted

Competing Products

8 competing products in Cluster Headache, Episodic

See all competitors
ProductCompanyStageHype Score
Galcanezumab 300 mg + PlaceboEli LillyPhase 3
77
GalcanezumabEli LillyPhase 3
77
Galcanezumab + PlaceboEli LillyPhase 3
77
candesartan cilexetil + placeboAstraZenecaPhase 2
52
SOM230 + PlaceboNovartisPhase 2
52
Bosutinib + ImatinibPfizerPhase 3
76
Eptinezumab + PlaceboLundbeckPhase 3
74
EptinezumabLundbeckPhase 3
74

Other Products from Brain Biotech

FCYC+Conventional treatment + conventional treatmentApproved
77
Escitalopram + PlaceboApproved
77
Sinemet CR + Placebo oral capsuleApproved
77
MethylphenidateApproved
77
Paliperidone Palmitate Injection (PP1M)Approved
77